Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
erlotinib + gefitinib + ginsenoside Rg3 + icotinib
- Development stage
- Unknown
- Lead developer
- Astellas Pharma
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
A combination of four drugs: erlotinib and gefitinib (both EGFR tyrosine kinase inhibitors used in the treatment of non-small cell lung cancer), ginsenoside Rg3 (a compound found in ginseng with potential anticancer properties), and icotinib (another EGFR tyrosine kinase inhibitor). Erlotinib and gefitinib work by inhibiting the epidermal growth factor receptor tyrosine kinase, blocking downstream signaling cascades that promote cancer cell proliferation.
02
Targets
EGFR T790M (Epidermal growth factor receptor T790M mutant)
Beyond the preview
Go deeper on erlotinib + gefitinib + ginsenoside Rg3 + icotinib.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on erlotinib + gefitinib + ginsenoside Rg3 + icotinib.